00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
18:58 , Feb 7, 2019 |  BC Week In Review  |  Company News

Xencor to co-develop IL-15 therapies with Genentech

Xencor Inc. (NASDAQ:XNCR) will receive $120 million up front in a deal to co-develop its IL-15 cytokine therapeutics, including XmAb24306, with Genentech Inc. The partners will evaluate combinations of XmAb24306 with products from Genentech's oncology...
23:41 , Feb 5, 2019 |  BC Extra  |  Company News

Xencor to co-develop IL-15 therapies with Genentech

Xencor Inc. (NASDAQ:XNCR) will receive $120 million up front in a deal to co-develop its IL-15 cytokine therapeutics, including XmAb24306, with Genentech Inc. The partners will evaluate combinations of XmAb24306 with products from Genentech's oncology...
00:56 , Jan 25, 2019 |  BC Innovations  |  Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...
00:44 , Jan 11, 2019 |  BC Extra  |  Preclinical News

UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop

University of Washington researchers published a Nature paper Wednesday detailing the construction of a synthetic protein that selectively binds to IL-2 to avoid toxicities that have previously overshadowed interest in the receptor as a therapeutic...
00:59 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 on Nov. 30 after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate...
23:45 , Nov 30, 2018 |  BC Extra  |  Clinical News

Fate to bring iPS cell therapy to clinic

Fate Therapeutics Inc. (NASDAQ:FATE) gained $1.26 to $15.36 Friday after announcing that FDA will allow the biotech to move forward with a clinical trial of its allogeneic NK cell therapy FT500, which Fate says would...
05:02 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...